We have further examined the mechanism by which phorbol ester-mediated protein kinase C (PKC) activation protects against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced cytotoxicity. We now report that activation of PKC targets death receptor signaling complex formation. Pre-treatment with 12-Otetradecanoylphorbol-13-acetate (PMA) led to inhibition of TRAIL-induced apoptosis in HeLa cells, which was characterized by a reduction in phosphatidylserine (PS) externalization, decreased caspase-8 processing, and incomplete maturation and activation of caspase-3. These effects of PMA were completely abrogated by the PKC inhibitor, bisindolylmaleimide I (Bis I), clearly implicating PKC in the protective effect of PMA. TRAIL-induced mitochondrial release of the apoptosis mediators cytochrome c and Smac was blocked by PMA. This, together with the observed decrease in Bid cleavage, suggested that PKC activation modulates apical events in TRAIL signaling upstream of mitochondria. This was confirmed by analysis of TRAIL death-inducing signaling complex formation, which was disrupted in PMA-treated cells as evidenced by a marked reduction in Fas-associated death domain protein (FADD) recruitment, an effect that could not be explained by any change in FADD phosphorylation state. In an in vitro binding assay, the intracellular domains of both TRAIL-R1 and TRAIL-R2 bound FADD: activation of PKC significantly inhibited this interaction suggesting that PKC may be targeting key apical components of death receptor signaling. Significantly, this effect was not confined to TRAIL, because isolation of the native TNF receptor signaling complex revealed that PKC activation also inhibited TNF receptor-associated death domain protein recruitment to TNF-R1 and TNF-induced phosphorylation of IB-␣. Taken together, these results show that PKC activation specifically inhibits the recruitment of key obligatory death domain-containing adaptor proteins to their respective membrane-associated signaling complexes, thereby modulating TRAIL-induced apoptosis and TNF-induced NF-B activation, respectively.
Death receptors belong to a subgroup of the tumor necrosis factor (TNF) 1 receptor/nerve growth factor superfamily. Members of this subfamily are characterized by a number of conserved cysteine-rich repeats within the extracellular domain and the presence of a "death domain" (DD) motif within the intracellular domain. The DD was first identified in the intracellular domain of TNF receptor-1 (TNF-R1) and was described as a region of ϳ80 amino acids containing a number of key residues that appeared to be critical for TNF-mediated cytotoxicity. These residues also appear to be highly conserved within other members of the death receptor subfamily (1) . TNF-related apoptosis-inducing ligand (TRAIL) was identified because of its high sequence homology to other TNF family members (2, 3) . The TRAIL receptor family is unusually complex in that it consists of at least four membrane-bound members. TRAIL-R1 (DR4) and -R2 (DR5, Killer, and TRICK2) are death receptors and contain a DD motif within the intracellular domain similar to CD95/Fas/APO-1 and TNF-R1 (1) . Two other receptors TRAIL-R3 (DcR1, LIT, and TRID) and -R4 (DcR2 and TRUNDD) lack or contain an incomplete DD and are therefore incapable of inducing apoptosis. Ectopic expression of TRAIL-R3 and -R4 has been demonstrated to attenuate TRAIL-induced apoptosis, and they are therefore often described as "decoy receptors" (4) .
TRAIL signals apoptosis through formation of a deathinducing signaling complex (DISC). Ligation of TRAIL-R1 and -R2 by TRAIL leads to rapid recruitment of the adaptor protein FADD/MORT1 (5) (6) (7) . FADD is a bipartite molecule with a C-terminal DD and an N-terminal death effector domain and appears to be a universal adaptor protein, because it is required for cytotoxicity induced by other death receptor subfamily members (8, 9) . FADD binding to the receptor occurs through a homophilic DD interaction while the death effector domain mediates the interaction with similar motifs in the prodomain of the initiator caspase, caspase-8. Procaspase-8 is activated at the DISC by an autocatalytic mechanism, which is dependent on the proximity of other procaspase-8 molecules (10) . Following activation, caspase-8 mediates apoptosis either by the direct activation of down-stream effector caspases or through cleavage of pro-apoptotic molecules such as the Bcl-2 homolog, Bid (11, 12) .
The importance of TRAIL as a potential therapeutic agent became obvious when it was demonstrated to be selectively toxic to transformed and tumor cells but not to the majority of normal cells (1) (2) (3) . These observations were confirmed in a number of in vivo studies where TRAIL was effective at reducing solid tumor growth and inducing regression of tumor cell xenografts (13) (14) (15) in the absence of the systemic toxicity observed with anti-Fas/CD95 or TNF treatment (16, 17) . The mechanism of this differential sensitivity was initially attributed to the presence of TRAIL "decoy receptors" on normal cells, however, recent studies have failed to correlate decoy receptor expression with TRAIL sensitivity (18, 19) , and there has been growing evidence to suggest that TRAIL resistance may instead be regulated intracellularly.
Several intracellular proteins have been implicated in providing resistance to TRAIL-induced apoptosis. The inactive caspase-8 homolog, cellular FLICE-inhibitory protein (c-FLIP), interferes with the activation of procaspase-8 at the DISC (20) , with high basal FLIP expression often correlating with resistance to TRAIL. In support of this, modulation of c-FLIP levels by metabolic inhibitors has been demonstrated to sensitize some of these resistant cell types to TRAIL-induced apoptosis (18, 21) . Other inhibitors include the inhibitor of apoptosis (IAP) proteins, in particular X-linked IAP (XIAP), which blocks apoptosis by directly inhibiting effector caspases (22) , and the Bcl-2 family members, Bcl-2 and Bcl-x L , which protect cells by inhibiting the mitochondrial changes that lead to activation of the Apaf-1/caspase-9 "apoptosome" complex (23) .
Pro-survival signaling pathways that have been implicated in TRAIL resistance include activation of the transcription factor NF-B (24, 25) , which in the case of TNF has been shown to act by up-regulating several anti-apoptotic genes, including c-IAP1 and -2 (26) . More recently, we have shown that TRAIL sensitivity can be modulated by activation or inhibition of NF-B and that, in some contexts, modulation of NF-B activation at the DISC may be a key determinant of sensitivity to TRAIL-induced apoptosis (27) . Recent observations have also implicated the protein kinase C (PKC) pathway in the protection of cells from apoptosis in a number of systems, including those induced by death receptor ligation (28 -31) . Activation of PKC abrogates CD95-induced apoptosis through inhibition of cell shrinkage and K ϩ efflux (28), but additionally modulates CD95 DISC formation by blocking FADD recruitment and thus caspase-8 activation (29, 30) . Activation of PKC has also been reported to inhibit TRAIL-induced apoptosis (30, 31) , but in this case the block was suggested to occur either at the level of proteolytic cleavage of procaspase-8 (30) or downstream of caspase-8-mediated Bid cleavage (31) . These observations prompted us to further examine the mechanism by which 12-O-tetradecanoylphorbol-13-acetate (PMA)-mediated PKC activation modulates TRAIL-induced cytotoxicity.
In the present study, we demonstrate that pre-treatment with PMA inhibits TRAIL-induced apoptosis in HeLa cells. TRAIL DISC formation was found to be disrupted in PMAtreated cells as judged by a reduction in recruitment of the obligatory adaptor molecule FADD and the initiator caspase-8. These effects of PMA were completely abrogated by the PKC inhibitor, bisindolylmaleimide I (Bis I), thus implicating a key role for PKC in the modulation of DISC components. Further support for this was provided by the observation that formation of the TNF receptor signaling complex was similarly affected with a decrease in TRADD recruitment being evident in PMAtreated cells. In summary, our results demonstrate that PKC activation modulates the ability of obligatory death domaincontaining receptor signaling components to interact with one another, thus providing another potential mechanism whereby cells can modulate TNF-induced NF-B activation and TRAILmediated cytotoxicity, respectively.
EXPERIMENTAL PROCEDURES
Materials-Bisindolylmaleimide I (GF 109203X) and PMA were purchased from Calbiochem (Nottingham, UK) and Sigma (Poole, UK), respectively. Recombinant human TRAIL (residues 95-281) was produced as previously described (32) , and recombinant human TNF (residues 55-233) was generated using the same methods (33) . Antibodies were sourced as follows: anti-FADD mAb and anti-TRADD mAb were from BD Transduction Laboratories (Heidelberg, Germany); anti-RIP mAb and anti-TRAF2 mAb were from BD Pharmingen; anti-poly(ADPribose) polymerase (PARP) mAb and anti-TRAIL-R1 and -R2 were from Alexis Corp. (Nottingham, UK); rabbit anti-Bid, rabbit anti-IB␣, and rabbit anti-phospho-IB␣ (Ser 32) were from Cell Signaling (Beverley, MA). Anti-caspase-3 was a kind gift from Dr. D. Nicholson (Merck Frosst, Quebec, Canada), and the caspase-8 mAb (C-15) (34) was a kind gift from Dr. P. H. Krammer (German Cancer Research Center, Heidelberg, Germany). TRAIL receptor antibodies (clones M271, M413, M430, and M444, respectively), used for flow cytometry, were a kind gift from Immunex Corp. (Seattle, WA) (35) . Horseradish peroxidase-conjugated secondary antibodies, goat anti-mouse and goat anti-rabbit, were obtained from Sigma and DAKO (Cambridge, UK), respectively. All other chemicals were of analytical grade and were from Sigma or Fisher (Loughborough, UK).
Cell Culture-All cell culture materials were from Invitrogen (Paisley, UK) and plasticware from BD Biosciences Labware (Bedford, MA). HeLa cells (ECCAC, Wiltshire, UK) were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, and maintained at 37°C with 5% CO 2 in a humidified atmosphere by routine passage every 3 days.
Determination of Apoptosis by Annexin V Staining-Apoptotic cells were quantified by measuring externalized phosphatidylserine (PS) assessed by Annexin V labeling and by propidium iodide uptake as described previously (36) .
Western Blotting-SDS-PAGE and immunoblotting were carried out as described previously (27) .
Analysis of Cytochrome c and Smac Release from MitochondriaMitochondrial release of cytochrome c and Smac was performed using a digitonin lysis method essentially as described previously (37, 38) .
Precipitation of the TRAIL DISC and TNF Signaling Complex-DISC precipitation was performed using biotin-labeled recombinant TRAIL (bTRAIL) or TNF (bTNF) essentially as described previously (7, 27, 33) , with the following modifications: cells were lysed with "lysis buffer" containing 30 mM Tris-HCl (pH 7.5), 150 mM NaCl, 10% (v/v) glycerol, 1% Triton X-100 (v/v), 10 mM ␤-glycerophosphate, 1 mM Na 3 VO 4 , 5 mM NaF, containing Complete TM protease inhibitors (Roche Applied Science), and streptavidin-Sepharose TM beads were used to precipitate TRAIL/TNF receptor complexes (Amersham Biosciences).
Analysis of TRAIL Receptors by Flow Cytometry-Control and treated HeLa cells were subjected to limited trypsinization, resuspended in blocking buffer (10% normal goat serum in phosphate-buffered saline (PBS)) and incubated for 30 min on ice to block nonspecific antibody binding. Cells were then labeled with anti-TRAIL receptor antibodies and analyzed by flow cytometry as described previously (39) .
Analysis of TRAIL Receptor Aggregation-To observe aggregated TRAIL receptors, DISCs were precipitated as described above and subjected to gel electrophoresis in the absence of reducing agents followed by immunoblotting with specific antibodies as has been described previously (40 -42) . Receptor aggregates appeared as higher molecular weight bands, corresponding to either dimers or trimers of the respective TRAIL receptors.
Expression of GST Fusion Proteins and in Vitro Interactions-GST fusion proteins were created by fusing glutathione S-transferase (GST) to the N terminus of the intracellular domains (ICDs) of TRAIL-R1 (residues 269 -468) and TRAIL-R2 (residues 209 -411). DNA encoding these residues was cloned in-frame into the EcoRI and XhoI sites of pGEX4T (Amersham Biosciences, Bucks, UK). Receptor fusion proteins were overexpressed in XA-90 cells, kindly provided by Prof. D. Riches (National Jewish Medical and Research Center, Colorado), by inducing with 1 mM isopropyl-D-thiogalactoside for 3 h, and cells were then lysed by sonication in 1.5% (w/v) Sarkosyl, containing 5 mM dithiothreitol and Complete TM protease inhibitors (Roche Applied Science). The dialyzed lysate was bound to 1.5 ml of washed glutathione-Sepharose beads (50% slurry in PBS) for 1 h at 4°C, the beads were washed twice in ice-cold PBS, and the amount of purified GST fusion protein was quantified by Coomassie Blue staining and comparison with bovine serum albumin standards. To assess GST-TRAIL-R-ICD protein binding, HeLa cells were either left untreated or treated with PMA (20 ng/ml) for 30 min, then washed once with PBS and harvested by trypsinization. Cell pellets were resuspended in 3 ml of lysis buffer (see above) and incubated on ice for 45 min. Lysates were cleared by centrifugation, and aliquots of the supernatant containing 5 mg of protein (10 mg/ml) were incubated for 16 h at 4°C with 10 g of purified GST-ICD fusion proteins bound to glutathione-Sepharose beads. Control pull-down assays were carried out using beads coated with purified GST alone. Bound proteins were pelleted by centrifugation at 200 ϫ g for 3 min, washed five times in PBS containing protease inhibitors, and released from beads by boiling for 5 min in SDS sample buffer. The interaction of FADD with GST-TRAIL-R-ICDs was assessed by Western blotting.
Analysis of FADD by Two-dimensional Gel Electrophoresis-Twodimensional electrophoresis was carried out using the IPGphor system (Amersham Biosciences). Briefly, TRAIL DISC samples were resuspended in rehydration buffer (8 M urea, 2% CHAPS, 2% IPG buffer, pH 4 -7 (Amersham Biosciences), trace bromphenol blue) and mixed at room temperature for 4 h. Samples were then applied to IPG (Immobilized pH Gradient) strips with a pH range of 4 -7. Strips were then subjected to active rehydration at 50 V for 12 h followed by isoelectric focusing (500 V for 30 min, 1000 V for 30 min, then 8000 V for 1 h). After focusing, strips were equilibrated in SDS equilibration buffer (50 mM Tris/HCl, pH 8.8, 6 M urea, 30% (w/v) glycerol, 2% SDS, trace bromphenol blue) for 15 min at room temperature. Second dimension electrophoresis and Western blotting were then carried out as described above.
RESULTS

PMA Inhibits TRAIL-induced Apoptosis in HeLa Cells-To
further elucidate the role of PKC in death receptor-induced apoptosis, HeLa cells were treated with the PKC activator, PMA, and its effect on TRAIL-induced apoptosis was assessed. Pre-treatment of HeLa cells with 20 ng/ml PMA completely abrogated TRAIL-induced apoptosis as measured by inhibition of both phosphatidylserine (PS) exposure and TRAIL-induced cleavage of the caspase-3/-7 substrate PARP (Fig. 1A) . Treatment with PMA alone was not cytotoxic to HeLa cells at the concentration used (data not shown).
To investigate the mechanism by which PMA protects cells from TRAIL, cell pellets were subjected to Western blotting for a number of components of the TRAIL receptor signaling pathway. Caspase-8 is known to be the apical caspase activated during TRAIL-induced apoptosis and is recruited and processed at the DISC in a FADD-and TRAIL-dependent manner (5-7). The caspase-8 zymogen exists as two splice forms, p55 and p53, which are activated in a two-step process involving the removal of the small subunit, p12, to generate p43 and p41 intermediates. A second cleavage then results in the removal of the large p18 subunit (43, 44) . When HeLa cells were treated with PMA for 30 min prior to the addition of TRAIL, there was a marked reduction in the activation of caspase-8 as judged by a decrease in generation of the large (p18) subunit and a concomitant increase in the amount of procaspase-8 (Fig. 1B) .
During receptor-mediated apoptosis procaspase-3 is processed by active caspase-8 between its large and small subunits to generate a p20/p12 caspase-3 intermediate. The large subunit (p20) then undergoes an autocatalytic activation step resulting in removal of the prodomain and generation of the fully mature p17 form (45) . In TRAIL-treated HeLa cells caspase-3 was processed to its fully mature p17 subunit (Fig. 1B) . However, although caspase-3 activity was inhibited in PMA-treated cells, as judged by inhibition of PARP processing (Fig. 1A) , caspase-3 was still processed but only to its p20 intermediate (Fig. 1B) . The presence of the p20, but not the p17, subunit suggested that maturation of the p20 subunit of caspase-3 was inhibited in cells pre-treated with PMA.
The pro-apoptotic Bcl-2 family member, Bid, is another known caspase-8 substrate. Cleavage of full-length Bid (p22) leads to the generation of a truncated form (p15, tBid), which is then is capable of triggering mitochondrial disruption via a Bax-and/or Bak-dependent process, ultimately leading to amplification of death receptor signaling through engagement of the Apaf-1/caspase-9 apoptosome pathway (11, 12, 46) . Bid was found to be processed in TRAIL-treated cells as judged by loss of the intact form. PMA pre-treatment markedly reduced this loss of Bid (Fig. 1B) , in agreement with the PMA-mediated inhibition of caspase-8 processing. Thus, PMA-mediated protection against TRAIL-induced apoptosis is characterized by inhibition of PS externalization, a reduction in caspase-8 activation, reduced cleavage of the pro-apoptotic Bcl-2 homolog, Bid, and incomplete maturation and activation of caspase-3.
Inhibition of PKC Can Reverse PMA-mediated Resistance to TRAIL-induced Apoptosis-To determine whether the inhibition of apoptosis and the changes observed following pre-treatment with PMA were the result of PKC activation, HeLa cells were preincubated with the PKC inhibitor, bisindolylmaleimide I (Bis I), prior to the addition of PMA. Bis I completely abrogated the protective effect afforded by PMA as judged by a reversal in Annexin V/PI staining ( Fig. 2A) . Preincubation with Bis I also reversed the PMA-mediated inhibition of caspase-8 processing and Bid cleavage. In addition, caspase-3 was fully processed and enzymatically active as judged by complete mat-
FIG. 1. PMA inhibits TRAIL-induced apoptosis in HeLa cells.
HeLa cells were pre-treated with PMA (20 ng/ml) for 30 min prior to exposure to TRAIL (1 g/ml) for the indicated time periods. A, apoptosis was assessed by Annexin V staining and flow cytometry as described under ''Experimental Procedures'' and by Western blotting using an antibody to the caspase-3/-7 substrate PARP. B, cells were further analyzed by Western blotting using antibodies to caspases-8 and -3 and the caspase-8 substrate Bid. FADD was used as a protein loading control and migrates as a doublet representing the phosphorylated and non-phosphorylated forms of this protein.
uration of the p20 subunit to p17 (Fig. 2B ) and cleavage of PARP ( Fig. 2A ). These data demonstrate that the protection observed with PMA pre-treatment was indeed mediated by PKC.
Several other reports have demonstrated that protein kinase C inhibitors, including the bisindolylmaleimides, can potentiate FasL/CD95L-induced apoptosis (29, 30, 47, 48) . However, in our model, though Bis I was able to specifically reverse the effects of PMA, co-treatment of cells with Bis I and TRAIL did not significantly potentiate TRAIL-induced apoptosis (data not shown).
Pre-treatment with PMA Blocks TRAIL-induced Mitochondrial Release of Cytochrome c and Smac/DIABLO-The lack of PARP cleavage observed with PMA pre-treatment (Fig. 1A ) strongly suggested that there was no active caspase-3 within these cells. Despite this, caspase-3 was clearly processed, albeit incompletely to its p20 intermediate (Fig. 1B) . Several recent reports have provided a possible explanation for these results. In these studies, the protection afforded by either Bcl-2 or Bcl-x L overexpression, lack of Bax, or by an unknown component in TRAIL-resistant melanomas led to incomplete caspase-3 activation in response to TRAIL or CD95L (38, 49 -51) . Lack of TRAIL-and/or CD95L-induced release of cytochrome c, and the mitochondrial XIAP antagonist Smac led to accumulation of the p20 subunit of caspase-3, which was subsequently shown to be inhibited by XIAP. By analogy, in our model, any PMA-mediated increase in XIAP levels would be predicted to lead to a similar accumulation of the p20 form of caspase-3. However, this is unlikely to be the case, because others have reported that PMA does not modulate the level of XIAP (41) . Another possibility was that PMA was instead inhibiting TRAIL-induced release of cytochrome c or the IAP antagonist, Smac, either directly or indirectly through inhibition of caspase activation upstream of the mitochondria.
To investigate this, the effect of PMA pre-treatment on TRAIL-induced mitochondrial perturbation was assessed. TRAIL treatment led to a time-dependent release of cytochrome c into the cytosol, which was concomitant with the mitochondrial release of Smac (Fig. 3) . Significantly, PMA pretreatment blocked the release of both cytochrome c and Smac, thus providing a possible explanation for the incomplete processing of caspase-3 in our model (Fig. 1B) . Consistent with its ability to reverse the effects of PMA (Fig. 2) , Bis I pre-treatment restored both cytochrome c and Smac release in response to TRAIL (Fig. 3) . Thus, the ability of PMA to inhibit TRAILinduced release of cytochrome c and Smac, together with the decrease observed in caspase-8 activation and Bid cleavage, strongly suggested that PMA was targeting the apical events of TRAIL signaling, upstream of mitochondria.
PMA Pre-treatment Inhibits the Recruitment of FADD and Caspase-8 to the TRAIL DISC-During death receptor-mediated apoptosis, caspase-8 can be processed by two mechanisms. The first is the activation of procaspase-8 as the apical caspase in a FADD and ligand-dependent manner at the DISC (44, 52, 53) . The second, which is redundant if the first is inhibited, is mediated via a cytochrome c/Smac-mediated amplification loop in which caspase-3 indirectly activates procaspase-8 through a caspase-6-dependent mechanism (54) . The reduction in caspase-8 processing observed with PMA pre-treatment (Figs. 1B and 2B) could, therefore, be a consequence of inhibition of this second pathway as judged by the effects of PMA on TRAILinduced release of cytochrome c and Smac (Fig. 3) . However, the PMA-mediated reduction in cleavage and/or full processing of two known caspase-8 substrates, namely Bid and caspase-3 (Figs. 1B and 2B ), suggested to us that PMA was instead modulating the initial activation of caspase-8.
To address this directly, we investigated the effect of PMA on DISC formation, the apical event in TRAIL-induced caspase activation. Binding of TRAIL resulted in rapid recruitment of the adaptor protein FADD to the DISC (Fig. 4) . Recruitment of FADD was concomitant with the presence of caspase-8 within the DISC precipitates. When TRAIL DISCs were isolated from cells pre-treated with PMA there was a marked reduction in FADD, and consequently caspase-8, recruitment. Consistent with that shown previously in whole cell lysates (Fig. 2) preincubation of these cells with the PKC inhibitor, Bis I, reversed the effects of PMA and restored FADD and caspase-8 within the DISC (Fig. 4) .
Clearly the observed reduction in FADD and caspase-8 recruitment to the DISC provides a mechanism whereby PMA pre-treatment may protect cells from TRAIL. This, together with the ability of Bis I to inhibit these effects, implicates a (1 g/ml) . A, apoptosis was assessed by Annexin V staining and by Western blotting using an antibody to PARP. B, activation of procaspases-8 and -3 and cleavage of Bid was assessed by Western blotting as described under ''Experimental Procedures.'' FADD was used as a protein loading control.
major role for PKC in modulating the apical events of TRAIL signaling.
PMA Pre-treatment Does Not Markedly Alter Cell Surface TRAIL Receptor Expression-Protein kinase C activators, such as PMA, can protect cells from TNF-induced cytotoxicity by reducing the number of cell surface receptors available for TNF binding through a process known as ''receptor shedding'' (55, 56) . Although, to date, there have been no reports of TRAIL receptor shedding, any decrease in cell surface TRAIL receptors would be predicted to result in a reduction in FADD recruitment and TRAIL DISC formation similar to that observed in PMA-treated cells (Fig. 4) .
To investigate this possibility, HeLa cells were treated either with PMA alone, or with Bis I prior to PMA, and cell surface TRAIL receptor expression was then assessed by flow cytometry using receptor-specific antibodies (35) . TRAIL-R1 was the predominant TRAIL receptor on unstimulated cells, although TRAIL-R2 was also present but at lower levels (Fig. 5) . No staining for TRAIL-R3 or -R4 was observed on HeLa cells (data not shown), consistent with a number of other reports suggesting that these receptors are mainly expressed intracellularly (57) . Treatment of cells with PMA resulted in a very modest decrease in cell surface TRAIL-R1 expression, which was partially recovered upon pre-treatment with Bis I (Fig. 5A) . In contrast, levels of TRAIL-R2 were largely unaffected by treatment with PMA or by PMA in combination with Bis I (Fig. 5B) .
The modest decrease in TRAIL receptor expression resulting from PMA pre-treatment suggested that this was not the primary mechanism by which PMA reduced TRAIL DISC formation/FADD recruitment. This led us to investigate other potential mechanisms by which PMA may modulate the TRAIL DISC.
Effect of PMA on TRAIL Receptor Aggregation-There appears to be a critical requirement for the aggregation of death receptors to initiate apoptotic signaling (58, 59) . Upon triggering, CD95 oligomerizes and forms SDS-stable aggregates, which can be resolved by SDS-PAGE in the absence of reducing agents. These aggregates form almost immediately after CD95 stimulation and correspond to dimeric and trimeric forms of the receptor (40) . To assess whether the ligand-induced formation of death receptor aggregates was affected by PMA pre-treatment, TRAIL DISCs were isolated and resolved by SDS-PAGE in the absence of reducing agents followed by immunoblotting with TRAIL-R1 and -R2-specific antibodies.
Treatment with TRAIL resulted in the formation of higher molecular weight species that appeared to correspond to dimeric and trimeric forms of the respective TRAIL receptors (Fig. 6) . TRAIL treatment also resulted in the loss of monomeric receptors, which is consistent with their aggregation into dimeric and trimeric forms. Formation of these higher order aggregates of TRAIL-R1 and -R2 required TRAIL binding at the cell surface, because they were largely absent in the unstimulated receptor controls (Fig. 6) . Significantly, pre-treatment of cells with PMA did not appear to markedly affect the formation of TRAIL receptor aggregates (Fig. 6) , suggesting that the PMA-mediated inhibition of FADD binding was not the result of a decrease in TRAIL-induced receptor aggregation PMA Pre-treatment Inhibits the Affinity of FADD for TRAIL-R1 and -R2-Another possible explanation for the reduced FADD recruitment observed in PMA-pre-treated cells . Cells were then pre-treated with or without PMA (20 ng/ml) for 30 min before exposure to TRAIL (1 g/ml) for the indicated times. Cytosolic fractions were then isolated as described under ''Experimental Procedures'' and analyzed by Western blotting for the presence of cytochrome c and Smac.
FIG. 4. PMA inhibits FADD recruitment to the TRAIL DISC. HeLa cells (3 ϫ 10
7 /treatment) were either pre-treated with Bis I (1 M, 30 min) followed by PMA (20 ng/ml), PMA alone, or vehicle alone followed by bTRAIL (1 g/ml). After the indicated times TRAIL receptor complexes (DISCs) were isolated as described under ''Experimental Procedures.'' The addition of beads alone to unstimulated cell lysates (u/s) was used to control for nonspecific interactions. Cell lysates, prior to receptor complex isolation, and receptor complexes were then analyzed for the presence of FADD and caspase-8. ( Fig. 4) was that that the affinity of FADD for the intracellular domain of TRAIL-R1 or -R2 was modulated by pre-treatment with PMA. To test this hypothesis, we fused the intracellular domain (ICD) of TRAIL-R1 and TRAIL-R2 to a glutathione S-transferase (GST) tag and expressed these GST-TRAIL-R1/ 2-ICD fusion proteins in Escherichia coli. By incubating glutathione beads pre-coated with these fusion proteins in lysates from untreated or PMA-treated cells we could assess whether PMA was in any way affecting the affinity of FADD for the respective TRAIL receptor ICDs.
Consistent with our earlier findings in the native TRAIL DISC (Fig. 4) , both GST-TRAIL-R1-ICD and GST-TRAIL-R2-ICD were able to precipitate FADD from control cell lysates (Fig. 7) . Interestingly, when the respective TRAIL-R ICDs were incubated with lysates from PMA-treated cells, the proportion of FADD precipitated was greatly reduced. Data from this in vitro binding assay support the suggestion that the reduced FADD recruitment observed in TRAIL DISCs isolated from cells pre-treated with PMA may be due to a decreased affinity of FADD for the ICDs of TRAIL-R1 and -R2.
PMA Treatment Does Not Alter the Phosphorylation State of FADD-
The observation that PMA-mediated PKC activation can protect against TRAIL (Figs. 1 and 2) , CD95, and TNFinduced cytotoxicity suggests that PMA may be targeting a component that is common to all three of these death ligand signaling pathways. One such candidate molecule is FADD, because it functions as the universal adaptor protein for CD95-, TNF-, and TRAIL-induced cell death signaling (8, 60) . Furthermore, in our model, recruitment of FADD into the TRAIL DISC was markedly reduced by pre-treatment with PMA (Figs. 4 and  7) . The FADD protein exists in two forms, a non-and a serinephosphorylated form (40) . To assess whether PMA was in some way altering the phosphorylation state of FADD, native TRAIL DISCs were isolated and precipitates were analyzed by twodimensional gel electrophoresis followed by Western blotting for FADD.
FADD was present as two discrete spots in control cell lysates, representing the phosphorylated (Fig. 8A, right spot) and unphosphorylated (Fig. 8A, left spot) forms of the protein. These two forms were also present in DISCs isolated from cells exposed to TRAIL, indicating that both forms of FADD are recruited to the TRAIL DISC in a ratio similar to that previously reported for the CD95 DISC (40, 44) . Despite overall FADD recruitment being reduced by PMA pre-treatment (Fig.  8B) , exposure to PMA did not alter the phosphorylation state of FADD as judged by there being no change in the intensity of the two FADD spots (Fig. 8A) . Taken together, these data show that FADD phosphorylation is not modulated by pre-treatment with PMA and that PKC is most probably acting elsewhere to inhibit FADD recruitment by the TRAIL DISC.
PMA-mediated PKC Activation Also
Modulates TNF Signaling-Clearly, because PMA-mediated PKC activation modulates the apical events of TRAIL signaling, it may exert similar effects on other TNF family members. To test this hypothesis, we investigated whether PMA could modulate those signaling events mediated by TNF␣. TNF signaling differs from TRAIL and CD95 in that its predominant signaling pathway is activation of NF-B. TNF negatively regulates its own cytotoxicity through an NF-B-mediated survival pathway (26) . Engagement of TNF-R1 by TNF leads to the recruitment of an intermediate adaptor protein, TRADD (TNF receptor-associated death domain protein), which then acts as a platform for the recruitment of other signaling molecules (61, 62) . RIP and TRAF2 are required for activation of the transcription factor NF-B, whereas FADD is reported to be responsible for apical caspase recruitment (8, (63) (64) (65) . TRAF2 recruitment is also required for TNF-mediated activation of c-Jun N-terminal kinase (JNK) (65) .
TNF receptor complexes were isolated using a similar method to that used previously for TRAIL, and because HeLa cells do not express TNF-R2, TNF-R1 complexes could be studied exclusively (66) . Treatment of cells with TNF led to immediate recruitment of TRADD, TRAF2, and RIP to the TNF precipitates (Fig. 9A) . Surprisingly, although TRADD was present in the precipitates as a single species, RIP and TRAF2 were subjected to some form of modification. Such modifications have been noted elsewhere and may be characteristic of polyubiquitination (33, 67, 68) . However, it should be noted that only those RIP and TRAF2 molecules recruited to the receptor precipitates were modified, because both proteins migrated as single species in similarly treated whole cell lysates (Fig. 9A) (33) . When TNF precipitates were isolated in the presence of PMA, the binding of TRADD was completely abolished (Fig. 9A) . RIP and TRAF2 binding was also inhibited by PMA pre-treatment, consistent with their recruitment being dependent on the obligatory intermediate adaptor protein, TRADD (69, 70) . Significantly, the binding of TRADD, RIP, and TRAF2 to TNF precipitates was restored when receptor complexes were isolated from cells pre-treated with Bis I prior to the addition of PMA (Fig. 9A) . These data clearly demonstrate that PMA-mediated PKC activation can modulate the apical events of TNF signaling.
HeLa cells are not susceptible to TNF-mediated cytotoxicity, even in the presence of protein synthesis inhibitors (data not shown), thus, we could not directly assess the effect of PMA on TNF-induced apoptosis. However, because both RIP and TRAF2 are required for TNF-mediated NF-B activation, any inhibition of their recruitment to the TNF receptor complex would be predicted to impair TNF-mediated NF-B activation. The effect of PMA on TNF-mediated NF-B activation, specif- ically the inducible phosphorylation of IB-␣ at Ser-32, was therefore assessed. Treatment of HeLa cells with TNF led to phosphorylation of IB-␣ within 5 min, which then decreased between 10 and 15 min with some recovery of phospho-IB-␣ levels evident by 60 min (Fig. 9B, left panel) . The well-documented loss and subsequent recovery of phospho-IB-␣ (71) was concomitant with an initial decrease in total cellular IB-␣ followed by its re-synthesis at 60 min (Fig. 9B, right panel) . Consistent with the observation that PMA inhibited the binding of RIP and TRAF2 to TNF-R1, PMA pre-treatment abolished TNF-induced phosphorylation of IB-␣ and the subsequent reduction in total cellular IB-␣. Significantly, preincubation with the PKC inhibitor, Bis I, completely restored TNF-induced phosphorylation of IB-␣ and the TNF-induced decrease and subsequent re-synthesis of IB-␣ (Fig. 9B) .
Taken together, these data suggest that PMA-mediated PKC activation modulates apical events in TNF signaling in a manner similar to that already observed for TRAIL, i.e. by inhibiting the recruitment of obligatory core components to the TNF receptor signaling complex, and implicates a more general role for PKC in modulating signaling by other TNF family members.
DISCUSSION
Previous reports have demonstrated that PMA-mediated PKC activation can protect cells from CD95-mediated apoptosis (29, 30, 41, 72, 73) . The exact nature of this inhibition was however disputed with different groups proposing that PKC modulated CD95-induced apoptosis at different levels. Some early reports suggested that PKC activation inhibited CD95-induced apoptosis upstream of caspase-8 activation (41, 73) ; however, Holmstrom and colleagues (72) subsequently reported that CD95 DISC formation and caspase-8 activity were unaffected by PKC activation. More recently it has been shown that FADD recruitment by CD95 is inhibited in PMA pretreated cells (29, 30) , suggesting that PKC in some way modulates CD95 DISC formation. Although several recent reports have indicated that PKC also inhibits apoptosis induced by TRAIL (30, 31, 74, 75) and TNF␣ (30, 75) , the mechanism of this effect is still not well understood. Moreover, it is not known whether a common mechanism could explain the inhibitory effects of PMA on the signaling pathways activated by these closely related death receptor ligands.
We show for the first time that activation of PKC leads to inhibition of TRAIL-induced apoptosis by interfering with a key apical event in TRAIL signaling, namely, recruitment of FADD to the DISC (Fig. 4) . A series of observations suggested to us that PKC activation was modulating TRAIL signaling at a step prior to mitochondrial engagement. First, PKC activation blocked TRAIL-induced PS exposure and PARP cleavage suggesting that caspase-3 activity was inhibited (Fig. 1) . Second, although caspase-3 activity was blocked, initial cleavage of caspase-3 to yield the immature p20 subunit was not completely inhibited by PMA (Fig. 2) , suggesting that the autocatalytic step of caspase-3 processing was being inhibited most likely by XIAP (38, 49) . Third, mitochondrial release of both cytochrome c and the IAP antagonist Smac was blocked by PMA (Fig. 3) , thus providing direct evidence that PKC activation was preventing engagement of the mitochondrial amplification arm of TRAIL signaling.
Previous studies had reported that PKC activation pre- TRAIL receptor complexes were then precipitated as described under ''Experimental Procedures.'' A, FADD phosphorylation status was analyzed by assessing the mobility of FADD by two-dimensional gel electrophoresis and Western blotting. B, the FADD content of whole cell lysates, lysates containing beads alone (u/s), and the TRAIL receptor complexes was also assessed by Western blotting following one-dimensional gel electrophoresis.
vented TRAIL-induced apoptosis by inhibiting a step downstream of both caspase-8 activation and Bid cleavage (31) . In the present study we utilized several approaches to address this issue. First, we examined the effect of PMA on TRAILinduced caspase-8 processing and Bid cleavage in whole cell lysates. In contrast to previous reports (31), we observed that PMA inhibited both caspase-8 processing and Bid cleavage (Fig. 2) . This argued for the effect of PMA on TRAIL-induced apoptosis occurring upstream of both caspase-8 and Bid, and prompted us to directly examine the effects of PMA on TRAIL DISC assembly. This revealed that PKC activation inhibited the recruitment of both FADD and caspase-8 to the DISC (Fig.  4) , thus demonstrating that a primary effect of PMA is mediated via inhibition of the "DD-DD-dependent" interaction between TRAIL-R1/-R2 and FADD at the DISC. Further support for this hypothesis was obtained using our in vitro binding assay, which revealed that recruitment of FADD to the intracellular domains of TRAIL-R1/-R2 was similarly significantly impaired in PMA-treated lysates (Fig. 7) .
Collectively, these observations inferred that a PMA-sensitive signaling mechanism was involved in modulating TRAILinduced FADD recruitment to the DISC. One possibility was that activation of PKC was either directly, or indirectly, modifying specific DISC components via a phosphorylation dependent-mechanism. Given that FADD is known to be phosphorylated (40), we hypothesized that PMA may modulate FADD phosphorylation and that this in turn may influence the affinity of FADD for TRAIL-R1/-R2. However, our observation that FADD phosphorylation status was unaltered by PMA (Fig. 8) , together with the finding that both forms of FADD were efficiently recruited to the TRAIL DISC (Fig. 8) , suggests that the phosphorylation state of FADD does not play a major role in TRAIL-induced apoptosis or in the PKC-mediated protection reported here. This is in agreement with that previously reported for CD95, where modulation of FADD phosphorylation status had no effect on the affinity of FADD for the CD95 DISC (30, 76) . Further support for the hypothesis that FADD itself is not the primary target of PKC is provided by our observation that TNF-induced recruitment of TRADD to TNF-R1 was similarly disrupted by pre-treatment with PMA (Fig. 9A) . This, together with the fact that TRADD is not phosphorylated, argues for PKC acting elsewhere to modulate the recruitment of these obligatory adaptor proteins to their respective membrane-associated signaling complexes.
How then does PMA affect the binding of FADD to the ICDs of TRAIL-R1/-R2? At least two possibilities exist. First, PMAmediated PKC activation may in some way modify the TRAIL-R1/-R2 receptor ICD, which results in a reduced binding affinity for FADD. However, Frankel and colleagues (77) have already demonstrated that TRAIL-R1 is constitutively phosphorylated in unstimulated peripheral blood lymphocytes, whereas TRAIL-R2 exists in an unphosphorylated form. These authors also demonstrated that PMA treatment did not affect the basal phosphorylation state of either TRAIL-R1 or -R2. Although we cannot exclude the possibility that in our model PMA is in some way modulating the phosphorylation state of TRAIL-R1/-R2, the observation that PMA inhibits FADD recruitment by TRAIL-R1/-R2-ICD in an in vitro binding assay (Fig. 7) suggests that modification of the TRAIL receptor ICDs may not be the primary mechanism whereby PMA inhibits TRAIL DISC formation. Second, there may be an as yet unidentified DISC component that either facilitates or is required for the interaction of FADD with the death domain of TRAIL-R1/-R2. In this respect, a number of studies suggest that phosphorylation may still play a role in death receptor-induced apoptosis as a number of novel proteins and kinases have been identified that associate specifically with the membrane proximal cytoplasmic tails of CD95 or TNF-R1 but not with their respective death domains (78, 79) . Furthermore, CD95 function has been reported to be affected by a number of kinases or phosphatases. One candidate is the phosphatase, Fas-associated phosphatase-1 (FAP-1), which has been reported to interact with the intracellular domain, specifically, the last three amino acids of CD95 (80) . FAP-1 acts as a negative regulator of CD95-induced apoptosis with caspase-8 activation being inhibited in FAP-1-transfected cells (81) . Another modulator of FIG. 9 . PMA inhibits TRADD recruitment by the TNF-R1 signaling complex and subsequent TNF-induced phosphorylation of IB-␣. HeLa cells were either pre-treated with Bis I (1 M, 30 min) followed by PMA (20 ng/ml, 30 min), PMA alone, or vehicle alone followed by bTNF (200 ng/ml) for the indicated times. A, cells (3 ϫ 10 7 / treatment) were washed and lysed, and TNF receptor complexes were isolated as described under ''Experimental Procedures.'' Cell lysates, prior to receptor complex isolation, and receptor complexes were then analyzed for the presence of TRADD, RIP, and TRAF2. Unstimulated receptors (u/s) represent precipitates resulting from the addition of beads alone to lysates from untreated cells. The asterisk indicates modified species of RIP and TRAF2 seen only in TNF receptor complexes. B, whole cells were subjected to Western blotting using a phosphospecific antibody that recognizes only the phosphorylated form of IB-␣ (Ser-32) and does not cross-react with the non-phosphorylated form of the protein (left panel) and a second antibody that recognizes total IB-␣ protein (right panel).
CD95 is Bruton's tyrosine kinase (BTK), a member of the Src-related Tec family of protein-tyrosine kinases (82) . BTK associates with CD95 via its kinase and pleckstrin homology domains and prevents the interaction of CD95 and FADD. Significantly, targeted disruption of the BTK gene in CD95-resistant B cells sensitizes these cells to CD95 (82) . More recently, it was reported that FAF1, a Fas-associating molecule, is also a component of the CD95 DISC, an effect mediated via FAF1 binding directly to both CD95 and caspase-8 (83) . In this context it may be significant that FAF1 shows similar proteininteracting characteristics to FADD. Whether FAP-1, BTK, or FAF1 are similarly involved in TRAIL/TNF-induced signaling or whether PKC activation can modulate death receptor-FAP-1/BTK/FAF1 binding or activity requires further investigation.
In this study we report a novel mechanism for PMA-mediated inhibition of TNF-induced signaling. The significance of this observation is 2-fold. First, it is the only report to date demonstrating that PKC activation modulates the apical events of TNF signaling, namely recruitment of the obligatory adaptor molecule TRADD to TNFR-1 (Fig. 9) . Second, our observation that PKC activation can modulate both TRAIL and TNF signaling by targeting the recruitment of obligatory adaptor protein(s) to the signaling complex, together with the finding that the CD95 DISC is similarly targeted (29, 30) , suggests a common mechanism underlying this phenomenon. Although the protein or factor that mediates this effect is currently unknown, further studies on the regulation of death receptor signaling may unveil a mechanism whereby phosphorylation of common signaling components confers cellular resistance to death ligand-induced apoptosis. Furthermore, our results with TNF highlight a potentially important role for PKC in modulating other signaling pathways activated by death receptor engagement, namely TNF-induced NF-B activation. Taken together, our results emphasize the importance of determining how protein kinase C activation functions to alter the ability of ''death receptor'' signaling components to interact with one another.
